The result of the US Supreme Court ruling which struck down the tariffs imposed by the US Administration under the International Emergency Economic Powers Act (IEEPA) removed one key instrument from President Trump’s tariff toolbox. Against this backdrop, President Trump has sought to rely on new legal authorities to continue his tariff agenda.
In particular, this includes the imposition of new 10% global tariffs under Section 122 of the Trade Act of 1974 (the Trade Act) as well as the launch of a significant number of investigations under Section 301 of the Trade Act to consider if tariffs are necessary as an outcome.
In response to the removal of the IEEPA tariffs, President Trump signed a proclamation imposing a temporary 10% tariff on most global merchandise imported into the United States under Section 122 of the Trade Act, which allows for duties for up to 150 days to correct serious “balance of payment deficits.”
These new tariffs have been in place since 24 February 2026 and will remain in place until 24 July 2026, unless extended by an act of Congress.
Given that Sections 301 and 232 of the Trade Act are provisions in respect of which President Trump’s authority is clearly delegated from Congress and will therefore be harder to challenge the legality of, the US Administration has placed greater reliance on making use of these tools to increase and / or introduce new tariffs.
In particular, the Office of the United States Trade Representative (USTR) has launched several new Section 301 investigations, including:
In general, Section 301 investigations can take up to a year to complete. However, in respect of the above, indications are that there will be accelerated timeframes for the investigations, with an unofficial target to be concluded by July 2026.
Additionally, the Bureau of Industry and Security (BIS) also has a number of active Section 232 investigations in place, including, amongst others, robotics and industrial machinery, processed critical minerals, copper, polysilicon.
In addition to the Section 232 tariffs which are currently in place in respect of steel, aluminium and automobile imports into the US, new tariffs under this authority were introduced on 2 April 2026 in respect of pharmaceuticals and pharmaceutical ingredients. These new tariffs impose a maximum 100% tariff on imported patented pharmaceuticals, while companies with approved onshoring plans face a reduced tariff of 20%. Generic drugs remain tariff-exempt. Tariff rates vary under current trade agreements with key partners, and negotiations on import adjustments will continue.
President Trump may impose tariffs on covered merchandise and derivative products once the Section 232 and 301 investigations are completed.
The removal of the IEEPA tariffs has not simplified trade into the US. There are however steps that US traders can take to reduce exposure and manage risk. In particular:
If you would like to further discuss this alert, reach out to our team or your PwC adviser.
Paul Cornick
Partner, Global Trade, PwC Australia
Gary Dutton
Partner, National Global Trade Leader, PwC Australia
Frances Ryan
Director, Global Trade, PwC Australia
Sarah Macchiavelli
Director, Global Trade, PwC Australia
Melissa Camilleri
Director, Global Trade, PwC Australia
Lara Jobling
Director, Global Trade, PwC Australia